WaveMan
WaveMan · Company
CTY · City Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CTY City Therapeutics (CTY) Insider Trading, Ownership & Congress Trades

CIK 0002143850
Activist 13D
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Conversions, 180 days
7
Codes C/M, not in net · no price filed

What the filings say about CTY

Insiders, 180 days
+$6.1M net bought
2 buyers
Activist stakes (13D), 180 days
1 filing
Largest: 25.6% of the class

City Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, CITY THERAPEUTICS, INC. insiders bought a net $6.1M of stock across 2 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
BUY
2026-10-19 SEC
170,000
$3.1M
n/a
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 1.2% of the 13,692,507 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: Director NELSEN ROBERT bought about $3.1M of CTY on Oct 19, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days.
BUY
2026-10-19 SEC
170,000
$3.1M
n/a
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 1.2% of the 13,692,507 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: Insider ARCH Venture Partners XII, LLC bought about $3.1M of CTY on Oct 19, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days.
2 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$6.1M over 180 days
+$6.1M over 90 days · +$6.1M of it by a 10%+ holder
more than 78% of its sector
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
no short interest reported
The situation: each line is one rule over one dataset
ARCH Venture Fund XII, L.P. disclosed a 5%+ stake (25.6%) in the last six months.
What changed in the last 30 days
Oct 26ARCH Venture Fund XII, L.P. filed a 13D for 25.6%
Oct 26ARCH Venture Partners XII, L.P. filed a 13D for 25.6%
Oct 26ARCH Venture Partners XII, LLC filed a 13D for 25.6%
Oct 26Robert Nelsen filed a 13D for 25.6%
Oct 26Keith Crandell filed a 13D for 25.6%

Watch CTY

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

Who owns CTY: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in CTY

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
ARCH Venture Fund XII, L.P.
Activist 13D · 2026-10-26
25.6%
ARCH Venture Partners XII, L.P.
Activist 13D · 2026-10-26
25.6%
ARCH Venture Partners XII, LLC
Activist 13D · 2026-10-26
25.6%
Robert Nelsen
Activist 13D · 2026-10-26
25.6%
Keith Crandell
Activist 13D · 2026-10-26
25.6%

CTY planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows a net $6.1M bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.

CTY Stock Sonar score 1/7 axes

Find similar shapesCompare
Insider conviction
89
Inputs
  • Net Form 4 buying (codes P and S), 180d$6.1M · 96 pct, universe of 3,403
  • Insider buyers, 180d2 · 81 pct, universe of 3,445
6 not measured: Profitability, Financial health, Growth, Institutional and government, Risk and compliance, US patents
  • Profitability needs 2 of 4 inputs, 0 present: not filed
  • Financial health needs 1 of 2 inputs, 0 present: not filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • Risk and compliance needs 1 of 4 inputs, 0 present: needs two 10-Ks with a Risk Factors section (not 20-F filers or stubs); no short interest or no free float on file; revenue under $50M or not filed, so a count cannot be scaled to size
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

1 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CTY filings, in plain words

Are City Therapeutics insiders buying or selling CTY?

In the 180 days to 2026-10-27, City Therapeutics insiders were net buyers, a net $6.1M across purchases and sales reported on Form 4, by 2 buyers.

Read the full summary

In the 180 days to 2026-10-27, City Therapeutics insiders were net buyers of CTY, a net $6.1M across purchases and sales reported on Form 4 by 2 buyers. Most of that figure, $6.1M, came from a holder of 10% or more rather than an officer or director. 2 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 25.6% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing